Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Quantum Dot Intermediate Band Solar Cells (QD-IBSCs) represent an innovative approach in solar energy technology, aiming to enhance the efficiency of solar cells beyond traditional limits.

Jan. 31, 2025 — Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defenders -- T cells -- lose their ability to ...

Jan. 30, 2025 — A new study has highlighted the potential of resveratrol, a natural compound found in grapes, blueberries, and raspberries, to enhance female fertility. The systematic review ...

Jay E Reeder Here we report that valproate does induce TSP1 expression in bladder cancer cell lines and that this is likely mediated through HDAC inhibition. The latter was evidenced by increased ...

Stem cells are cells that have the capacity to self-renew by dividing and to develop into more mature, specialised cells. Stem cells can be unipotent, multipotent, pluripotent or totipotent ...

In conclusion, we confirm decreased proliferation of bladder cancer cells by treatment with HDAC inhibitors and show increased expression of TSP1 in bladder cancer by this class of drug.

we analyzed the expression and distribution of G-CSF in 112 upper tract urothelial carcinoma (UTUC) samples with immunohistochemistry. In normal urothelium, G-CSF expression was weak or absent, ...

A ransomware group called RansomHouse appears to have been responsible for an attack on Cell C that compromised the data of some of its clients. A ransomware group called RansomHouse appears to have ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...

Cystoscopy-Based Standard Follow-Up In Patients With Low/Intermediate Risk Bladder Cancer IBCN 2023 ... Tailored Therapeutic Options and Determinants of Plasticity in Sarcomatoid Urothelial Bladder ...

In oncology, TYRA-300 is being studied in metastatic urothelial cancer (mUC) and intermediate-risk NMIBC. For mUC, TYRA-300 is currently undergoing evaluation in a multicenter, open-label, phase 1/2 ...